Cidara Therapeutics Inc. (CDTX)

NASDAQ: CDTX · Real-Time Price · USD

21.81

0.92 (4.43%)

At close: May 01, 2025, 3:59 PM

22.40

2.71%

Pre-market: May 02, 2025, 05:23 AM EDT

4.43% (1D)

Bid	16.42
Market Cap	238.9M
Revenue (ttm)	8.77M
Net Income (ttm)	-167.58M
EPS (ttm)	-26.82
PE Ratio (ttm)	-0.81
Forward PE	-2.04
Analyst	Buy

Ask	26.79
Volume	134,470
Avg. Volume (20D)	140,359
Open	20.80
Previous Close	20.89
Day's Range	20.80 - 22.80
52-Week Range	10.14 - 28.42
Beta	0.89

About CDTX

Cidara Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of long-acting anti-infectives for the treatment and prevention of infectious diseases and oncology in the United States. The company's lead product candidate is rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Apr 15, 2015

Employees 38

Stock Exchange NASDAQ

Ticker Symbol CDTX

Website https://www.cidara.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for CDTX stock is "Buy." The 12-month stock price forecast is $35, which is an increase of 60.48% from the latest price.

Stock Forecasts

Why Price Moved

5 months ago

+15.41%

Cidara Therapeutics shares are trading higher. The... Unlock content with Pro Subscription

News

2 days ago · zacks.com

Are You Looking for a Top Momentum Pick? Why Cidara Therapeutics (CDTX) is a Great Choice

Does Cidara Therapeutics (CDTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 month ago · zacks.com

Wall Street Analysts Predict a 64.5% Upside in Cidara Therapeutics (CDTX): Here's What You Should Know

The consensus price target hints at a 64.5% upside potential for Cidara Therapeutics (CDTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

2 months ago · seekingalpha.com

Bullish On Cidara Therapeutics As It Doubles Down On CD388 For Universal Flu Prevention

Cidara Therapeutics is leveraging its Cloudbreak platform to develop CD388 for universal influenza prophylaxis. Fortunately, they recently enrolled 5,000 subjects in its Phase 2b trial to assess CD388...